AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02649010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enlite 3 Sensor
Description: Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
Study NCT00860275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 50 mg, once, Day 1
Study NCT00860275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163 + Ketoconazole
Description: (BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
Study NCT00860275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Tablet, Oral, 400 mg, daily, 16 days
Study NCT00589121 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
Study NCT00589121 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
Study NCT04997980 — intervention group
Intervention type: DRUG
Intervention: Amiodarone Injection
Study NCT00856037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00856037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00856037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00856037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given PO
Study NCT01423227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: One home visit plus weekly telephone calls for 8 weeks
Study NCT01423227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-based pulmonary rehabilitation
Description: Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
Study NCT02025959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
Study NCT01651221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habituation
Description: Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
Study NCT01270074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
Study NCT01270074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo control
Description: inert liquid preparation will be given three times per week from three months of age to three years of age
Study NCT00201643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone or Dexamethasone (2nd course of ACS)
Description: Course of Betamethasone or Dexamethasone
Study NCT00201643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Course of Placebo (NS)
Study NCT00860275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Tablet, Oral, 1 day 400 mg then 3 days 200 mg
Study NCT00847808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR QD
Description: Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
Study NCT03994354 — intervention group
Intervention type: PROCEDURE
Intervention: J-P drainage and cutaneous penrose drainage insertion
Description: Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
Study NCT03814096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
Description: Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
Study NCT04431167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living well with Lupus
Description: The lifestyle change intervention will involve two constructs: increasing the level of physical activity and improving eating habits, each with its own specific domains and goals. It will be based on a structured program of physical exercises and selection of individualized goals in the domains of transportation, leisure and work to reduce sedentary behavior with the aim of increasing the level of physical activity, as well as establishing changes in dietary aspects, involving consumption domains, structure, behavior and eating attitude using nutritional counseling techniques.
Study NCT04119024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04119024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04119024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04119024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04119024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04119024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT scan
Study NCT04119024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Description: Given IV
Study NCT04119024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04119024 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03549390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Light-moderate intensity physical activities
Study NCT01419327 — intervention group
Intervention type: DRUG
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet
Description: Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
Study NCT01791374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
Study NCT01791374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilotumumab
Description: Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Study NCT02686827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Vitamin D3 analogue
Study NCT02686827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for paricalcitol)
Description: Injection fluid to mimic paricalcitol injection
Study NCT02909764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Group
Description: Breakfast Cereal
Study NCT03106168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of mandibular molar
Description: Patients who require extraction of mandibular molars will be submitted to surgery
Study NCT04598503 — intervention group
Intervention type: OTHER
Intervention: full history and clinical examination
Description: For each case, a detailed perinatal and maternal and family history were obtained by interviewing questionnaire. Diagnosis of congenital anomalies was based on clinical evaluation of newborn babies by the neonatologist and other appropriate investigations such as radiography, ultrasonography, echocardiography and chromosomal analysis etc... Classification of anomalies is done by systems according to WHO international classification of diseases (ICD10) \[10\]. Data was entered into excel data sheet and appropriate statistical analysis was performed. The prevalence was calculated by dividing the number of CA during the 6 months (173) by the total number of admission during this period (753).
Study NCT00860275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163 + Fluconazole
Description: (BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
Study NCT04224012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and respiratory therapy
Description: Three weeks in-Hospital Rehabilitation program with continuation of exercise Training at home
Study NCT02726100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMARTHealth Diabetes
Description: SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
Study NCT01974778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal
Description: Meal
Study NCT01974778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meal
Description: Meal
Study NCT03141905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sick-Day Protocol
Description: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
Study NCT03141905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Standard clinical care
Study NCT03066349 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
Study NCT03152058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Certolizumab \[400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter\] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention.
Study NCT06607354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grass fed lamb
Description: This study investigated the impact of consuming grass finished lamb on total blood plasma and blood plasma phospholipids (PL) FA and on cardiovascular risk factors, including heart rate, blood pressure (BP), HDL-cholesterol, LDL-cholesterol, and TAG cholesterol, in humans.
Study NCT05146752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extremely low frequency electromagnetic fields
Description: extremely low frequency electromagnetic fields
Study NCT05146752 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: routine care
Description: routine care
Study NCT03311867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethibond Suture
Description: Cerclage placement with ethibond
Study NCT03311867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prolene Suture
Description: Cerclage placement with prolene
Study NCT02781324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Spinal Fusion
Study NCT02781324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior Spinal Fusion
Study NCT02781324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Bone Scalpel
Study NCT00971217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
Study NCT00971217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioural Therapy
Description: Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
Study NCT02430558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OD-PHOENIX
Description: Decellularized, freeze-dried, irradiated osteochondral allograft
Study NCT04084496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Study NCT03451396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast
Description: All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
Study NCT04324229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 6 MG/ML [Victoza]
Description: Starting dose of liraglutide 0.6 mg will be administered for one week, after which dose will be escalated to liraglutide 1.2 mg for one week and thereafter liraglutide 1.8 mg s.c. daily injections.
Study NCT04324229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Starting dose of placebo 0.1 ml will be administered for one week, after which dose will be escalated to placebo 0.2 ml for one week and thereafter placebo 0.3 ml s.c. daily injections.
Study NCT03011996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR 500mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study NCT03011996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLR 500mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study NCT03011996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg
Description: Cohort 1: bid for 5 days Cohort 2: bid for 7 days
Study NCT03396276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suboxone
Description: 8mg of buprenorphine/2mg of naloxone
Study NCT03396276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief counseling in the ED
Description: Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers.
Study NCT03396276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral to outpatient treatment
Description: A referral will be made to one of the affiliated MAT clinics.
Study NCT03396276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up coaching
Description: A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
Study NCT01967147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylene Glycol, 0.6% eye drops
Description: Commercially available eye drops used during Treatment Phase
Study NCT01967147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative-free 0.9% Saline solution
Description: Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
Study NCT01844024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: misoprostol by midwife
Description: Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
Study NCT02081430 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Manipulation
Study NCT02081430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper trapezius stretch
Study NCT02588105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0156
Description: All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
Study NCT02588105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Module 1 combination with olaparib
Study NCT02588105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Module 2 combination with irinotecan/FOLFIRI
Study NCT02588105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Module 2 combination with irinotecan/FOLFIRI
Study NCT02588105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Module 2 combination with irinotecan/FOLFIRI
Study NCT02207504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an ATP-competitive small-molecule inhibitor of the ALK, c-Met/HGFR, RON, and ROS receptor tyrosine kinases.
Study NCT02207504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is an androgen receptor signaling inhibitor.
Study NCT01056705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
Study NCT01056705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
Study NCT01056705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
Study NCT01056705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Poliomyelitis Vaccine
Description: Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
Study NCT01056705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Salk strains).
Description: 3x0.5ml intramuscular injections, one month apart.
Study NCT04270591 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Glumetinib
Description: The investigational product will be orally administrated when fasting at dose level of 300mg QD
Study NCT01980680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Study NCT01980680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone and Estradiol